The monitoring of chimerism has become a routine diagnostic instrument at centers performing allogeneic stem cell or bone marrow transplantation. Despite the widespread use of molecular techniques permitting the assessment and the surveillance of donor-and recipient-derived hemopoiesis, there have been no international efforts to standardize the technical approaches, and to provide a basis for the comparison of diagnostic results. We believe that in this rapidly growing field there is a need for standardization directed towards optimum diagnostic support for clinical decision making.
In this issue, Leukemia presents the first contributions to the Debate, illustrating some of the ideas which we hope will stimulate discussion of both technical and clinical aspects of chimerism testing. The first paper (Dubovsky et al) demonstrates the clinical implications of the results of early kinetics of chimerism in children with leukemia and non-malignant disorders. The second paper (Peters et al) addresses the role of molecular monitoring in stem cell transplantation from HLA-mismatched parental donors. The third paper (Bader et al.) discusses the relevance of therapy based on the detection of increasing mixed chimerism in children with leukemia and myelodysplastic syndrome.
In the technical part of the debate, we would like to discuss different methodological approaches, and to extract the best of the currently available techniques as a basis for optimized diagnostic strategies. Together we will try to define appropriate sensitivity standards and adequate controls for quality-assured molecular diagnosis. Based on the results of this debate and the current state of the art, we would like to establish generally accepted standards for chimerism testing in the light of the possible clinical implications. An artificial consensus will not be forced, however, and it is understood that standards need to be revised. In the clinically oriented part of the debate, we would like to discuss the optimum timing of chimerism analysis, and the therapy options inferable from molecular monitoring in different transplant settings.
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Contributions to the Debate should be labeled 'Round Table on Chimerism Testing', and sent to the LEUKEMIA office in Paris which will transmit the manuscripts to the Moderator of the Debate (T Lion). There is no limitation to the number of participants in the Debate. The contributions can be short notes of up to 2500 words with a few references, regular papers or editorials.
